AMPH and Alzheimer disease: Moreover, we explore the combination of CSF proteins reflecting synaptic damage such as GAP43, NRGN, SNCB and amphiphysin (AMPH) in pairs with other brain-derived proteins to evaluate their combined ability to reflect disease pathology and hence their potential to be used in clinical trials to assess the efficacy of new AD therapies.